TQS 621
Alternative Names: TQS-621Latest Information Update: 12 Apr 2023
Price :
$50 *
At a glance
- Originator Tranquis Therapeutics
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Myeloid cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
- Research Alzheimer's disease
Most Recent Events
- 12 Apr 2023 Early research in Alzheimer's disease in USA (unspecified route),prior to April 2023 (Tranquis Therapeutics pipeline, April 2023)
- 12 Apr 2023 Tranquis Therapeutics plans a clinical trial in Alzheimer's disease and Parkinson's disease (unspecified route) (Tranquis Therapeutics pipeline, April 2023)
- 26 May 2021 Preclinical trials in Parkinson's disease in USA (unspecified route), prior to June 2022